Narcolepsy with cataplexy

被引:553
作者
Dauvilliers, Yves
Amulf, Isabelle
Mignot, Emmanuel
机构
[1] CHU Montpellier, Hop Guidechauliac, Serv Neurol, F-34295 Montpellier 5, France
[2] INSERM, U888, Montpellier, France
[3] Assistance Publ Hop Paris, Federat Pathol Sommeil, Paris, France
[4] Stanford Univ, Howard Hughes Med Inst, Palo Alto, CA 94304 USA
[5] Stanford Univ, Ctr Narcolepsy, Palo Alto, CA 94304 USA
关键词
D O I
10.1016/S0140-6736(07)60237-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Narcolepsy with cataplexy is a disabling sleep disorder affecting 0.02% of adults worldwide. It is characterised by severe, irresistible daytime sleepiness and sudden loss of muscle tone (cataplexy), and can be associated with sleep-onset or sleep-offset paralysis and hallucinations, frequent movement and awakening during sleep, and weight gain. Sleep monitoring during night and day shows rapid sleep onset and abnormal, shortened rapid-eye-movement sleep latencies. The onset of narcolepsy with cataplexy is usually during teenage and young adulthood and persists throughout the lifetime. Pathophysiological studies have shown that the disease is caused by the early loss of neurons in the hypothalamus that produce hypocretin, a wakefulness-associated neurotransmitter present in cerebrospinal fluid. The cause of neural loss could be autoimmune since most patients have the HLA DQB1*0602 allele that predisposes individuals to the disorder. Treatment is with stimulant drugs to suppress daytime sleepiness, antidepressants for cataplexy, and gamma hydroxybutyrate for both symptoms. Because narcolepsy is an under-recognised disease, it is important that general practitioners and other primary health-care workers identify abnormal daytime sleepiness early.
引用
收藏
页码:499 / 511
页数:13
相关论文
共 136 条
[1]  
Abad Vivien C, 2004, Expert Opin Emerg Drugs, V9, P281, DOI 10.1517/14728214.9.2.281
[2]   MAZINDOL IN LONG-TERM TREATMENT OF NARCOLEPSY [J].
ALVAREZ, B ;
DAHLITZ, M ;
GRIMSHAW, J ;
PARKES, JD .
LANCET, 1991, 337 (8752) :1293-1294
[3]  
Anic-Labat S, 1999, SLEEP, V22, P77
[4]  
[Anonymous], NARCOLEPSY
[5]  
[Anonymous], 2005, INT CLASSIFICATION S
[6]   Kleine-Levin syndrome: a systematic review of 186 cases in the literature [J].
Arnulf, I ;
Zeitzer, JM ;
File, J ;
Farber, N ;
Mignot, E .
BRAIN, 2005, 128 :2763-2776
[7]   Parkinson's disease and sleepiness - An integral part of PD [J].
Arnulf, I ;
Konofal, E ;
Merino-Andreu, M ;
Houeto, JL ;
Mesnage, V ;
Welter, ML ;
Lacomblez, L ;
Golmard, JL ;
Derenne, JP ;
Agid, Y .
NEUROLOGY, 2002, 58 (07) :1019-1024
[8]   Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study [J].
Auger, RR ;
Goodman, SH ;
Silber, MH ;
Krahn, LE ;
Pankratz, VS ;
Slocumb, NL .
SLEEP, 2005, 28 (06) :667-672
[9]   The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A) [J].
Bassetti, C ;
Gugger, M ;
Bischof, M ;
Mathis, J ;
Sturzenegger, C ;
Werth, E ;
Radanov, B ;
Ripley, B ;
Nishino, S ;
Mignot, E .
SLEEP MEDICINE, 2003, 4 (01) :7-12
[10]   Narcolepsy - Selective hypocretin (orexin) neuronal loss and multiple signaling deficiencies [J].
Bassetti, CL .
NEUROLOGY, 2005, 65 (08) :1152-1153